BioMarin Pharmaceutical Inc. (BMV:BMRN)

Revenue

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2011 - 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	2011 - 2020
VOXZOGO Revenue	862.03M	735.09M	Log In	Log In	Log In	Upgrade
VIMIZIM Revenue	777.62M	739.78M	Log In	Log In	Log In	Upgrade
NAGLAZYME Revenue	475.18M	479.58M	Log In	Log In	Log In	Upgrade
PALYNZIQ Revenue	408.40M	355.05M	Log In	Log In	Log In	Upgrade
ALDURAZYME Revenue	198.16M	183.89M	Log In	Log In	Log In	Upgrade
BRINEURA Revenue	184.73M	169.08M	Log In	Log In	Log In	Upgrade
KUVAN Revenue	104.52M	120.90M	Log In	Log In	Log In	Upgrade
ROCTAVIAN Revenue	33.44M	26.07M	Log In	Log In	Log In	Upgrade
Total Net Product Revenue	3.04B	2.81B	Log In	Log In	Log In	Upgrade
Royalty and Other Revenue	49.93M	44.47M	Log In	Log In	Log In	Upgrade
Revenue (Other)	-33.44M	-26.07M	Log In	Log In	Log In	Upgrade
Revenue (Total)	3.09B	2.85B	Log In	Log In	Log In	Upgrade

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2011 - 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	2011 - 2020
Royalty and Other Revenue	49.93M	44.47M	Log In	Log In	Log In	Upgrade
United States Revenue	1.06B	924.81M	Log In	Log In	Log In	Upgrade
Europe Revenue	889.18M	829.03M	Log In	Log In	Log In	Upgrade
Latin America Revenue	387.18M	378.08M	Log In	Log In	Log In	Upgrade
Rest of World Revenue (Pre-Q3 2024)	-	-	Log In	Log In	Log In	Upgrade
Rest of World Revenue (Post-Q2 2024)	512.34M	493.63M	Log In	Log In	Log In	Upgrade
Revenue (Other)	198.16M	183.89M	Log In	Log In	Log In	Upgrade
Revenue (Total)	3.09B	2.85B	Log In	Log In	Log In	Upgrade

Updated Sep 30, 2025. Data Source: Fiscal.ai.